MESOBLAST LIMITED - Announcements

Market Cap $1.238B Add to my watchlist

Healthcare Biotechnology

Mesoblast Limited is an Australia-based is developing a range of late-stage product... Mesoblast Limited is an Australia-based is developing a range of late-stage product candidates derived from its proprietary mesenchymal lineage cell therapy technology platforms. The Company’s Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic refractory inflammatory bowel disease. Its Rexlemestrocel-L is mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of advanced chronic heart failure (CHF) and chronic low back pain (CLBP) due to degenerative disc disease. Two products are commercialized in Japan and Europe by the Company’s licensees, and it has a commercial partnership in Europe and China for certain Phase III assets.More

RCE'S BREAKTHROUGH

Recce Pharmaceuticals (ASX:RCE) is stepping up its trial activities in Australia’s nearest Asian neighbour, Indonesia. Recce’s flagship anti-infective, R327, can be applied as a gel – and this gel-based version of the drug has been of specific interest...

Announcements

Filter Results

All Price Sensitive Only

MSB	Prospectus for Warrants Related to Oaktree Facility		03/03/23	509.39KB	Share
MSB	DREAM HF Trial Published in JACC	PRICE SENSITIVE	28/02/23	226.95KB	Share
MSB	MSB Q2 Financial Results and Operational Highlights	PRICE SENSITIVE	28/02/23	408.95KB	Share
MSB	Second Quarter Results Presentation		28/02/23	1.57MB	Share
MSB	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/23	1.67MB	Share
MSB	Mesoblast Second Quarter Financial Results Webcast		27/02/23	115.2KB	Share
MSB	Remestemcel Clinical and Potency Studies Presented at Tandem		17/02/23	175.63KB	Share
MSB	FDA Grants RMAT Designation for Rexlemestrocel-L in CLBP		09/02/23	187.83KB	Share
MSB	Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD	PRICE SENSITIVE	01/02/23	195.59KB	Share
MSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/23	419.11KB	Share
MSB	Appendix 3G, Appendix 3H and Appendix 3Ys		16/01/23	575.59KB	Share
MSB	Biotech Showcase 2023 Presentation in San Francisco		10/01/23	1.67MB	Share
MSB	Extension of Undrawn US$30 million Facility	PRICE SENSITIVE	23/12/22	161.36KB	Share
MSB	Proposed issue of securities - MSB		23/12/22	25.9KB	Share
MSB	Appendix 3G, Appendix 3H and Appendix 3Y		02/12/22	582.16KB	Share
MSB	Amended Constitution		24/11/22	626.04KB	Share
MSB	Results of Meeting		23/11/22	187.96KB	Share
MSB	Chairman's Address to Shareholders		23/11/22	192.3KB	Share
MSB	Long-Term Survival for Acute GvHD Treatment with Remestemcel	PRICE SENSITIVE	23/11/22	189.85KB	Share
MSB	MSB Q1 Financial Results and Operational Highlights	PRICE SENSITIVE	23/11/22	439.61KB	Share
MSB	CEO First Quarter Results and 2022 AGM Presentation		23/11/22	2.06MB	Share
MSB	First Quarter Financial Results on Form 6-K	PRICE SENSITIVE	23/11/22	500.21KB	Share
MSB	Mesoblast First Quarter Financial Results Webcast		21/11/22	113.78KB	Share
MSB	Removal of Amendment to Constitution About Virtual Meetings		15/11/22	123.99KB	Share
MSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/22	419.32KB	Share
MSB	Notice of Annual General Meeting and Proxy Form		24/10/22	443.56KB	Share
MSB	Annual Report to Shareholders		24/10/22	6.59MB	Share
MSB	Appendix 4G and Corporate Governance Statement		24/10/22	412.08KB	Share
MSB	Notification of cessation of securities - MSB		14/10/22	21.69KB	Share
MSB	Submits New Information to FDA IND File for SR-aGVHD	PRICE SENSITIVE	03/10/22	168.87KB	Share
MSB	Change of Director's Interest Notice		20/09/22	229.59KB	Share
MSB	Change of Director's Interest Notice		12/09/22	226.98KB	Share
MSB	MSB Annual Financial Results and Operational Highlights	PRICE SENSITIVE	31/08/22	386.1KB	Share
MSB	Annual Financial Results Presentation		31/08/22	1.83MB	Share
MSB	Preliminary Final Report	PRICE SENSITIVE	31/08/22	3.16MB	Share
MSB	Mesoblast 2022 Full Year Financial Results Webcast		30/08/22	116.05KB	Share
MSB	Director Appointment		18/08/22	133.74KB	Share
MSB	Initial Director's Interest Notice		18/08/22	305.67KB	Share
MSB	Final Director's Interest Notice		18/08/22	220.39KB	Share
MSB	Ceasing to be a substantial holder - Tiga Trading Pty Ltd		16/08/22	306.57KB	Share
MSB	Ceasing to be a substantial holder from TEK		16/08/22	324.86KB	Share
MSB	Ceasing to be a substantial holder from TOP		16/08/22	320.64KB	Share
MSB	Change in substantial holding		16/08/22	491.21KB	Share
MSB	Cleansing Notice		12/08/22	176.58KB	Share
MSB	Appendix 2A		12/08/22	357.17KB	Share
MSB	Appendix 3B		09/08/22	652.66KB	Share
MSB	US$45 Million Private Placement to Major Shareholders	PRICE SENSITIVE	09/08/22	157.61KB	Share
MSB	Reinstatement to Quotation	PRICE SENSITIVE	09/08/22	85.62KB	Share
MSB	Voluntary Suspension	PRICE SENSITIVE	08/08/22	221.75KB	Share
MSB	Trading Halt	PRICE SENSITIVE	04/08/22	206.88KB	Share
MSB	Pause in Trading	PRICE SENSITIVE	04/08/22	116.13KB	Share
MSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/07/22	444.42KB	Share
MSB	Rexlemestrocel-L Improves LVEF, Preceding Reduction in MACE	PRICE SENSITIVE	19/07/22	185.89KB	Share
MSB	Appendix 3H and Appendix 3Y		14/07/22	350.16KB	Share
MSB	Rexlemestrocel-L to be Highlighted on Heart Failure Panel		12/07/22	167.56KB	Share
MSB	Mesoblast CLBP Event with Key Opinion Leaders		21/06/22	168.79KB	Share
MSB	Chronic Low Back Pain KOL Event Presentation		21/06/22	6.92MB	Share
MSB	Litigation Update		14/06/22	172.01KB	Share
MSB	Mesoblast to Host KOL Event on Chronic Low Back Pain		09/06/22	168.93KB	Share
MSB	Third Quarter Results Presentation	PRICE SENSITIVE	01/06/22	2.69MB	Share
MSB	MSB Q3 Financial Results and Operational Highlights	PRICE SENSITIVE	01/06/22	402.97KB	Share
MSB	Third Quarter Financial Results on Form 6-K	PRICE SENSITIVE	01/06/22	577.99KB	Share
MSB	Mesoblast Q3 Financial Results Webcast		31/05/22	115.5KB	Share
MSB	Remestemcel-L Survival Outcomes in COVID-19 ARDS Patients		31/05/22	179.19KB	Share
MSB	Ceasing to be a substantial holder		30/05/22	1.08MB	Share
MSB	Becoming a substantial holder		20/05/22	1.39MB	Share
MSB	Litigation Update		19/05/22	172.93KB	Share
MSB	Ceasing to be a substantial holder		03/05/22	1.05MB	Share
MSB	Ceasing to be a substantial holder		02/05/22	162.97KB	Share
MSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/04/22	443.8KB	Share
MSB	Becoming a substantial holder		19/04/22	1.29MB	Share
MSB	Appendix 3G and Appendix 3H		14/04/22	428.72KB	Share
MSB	Company Secretary Appointment		06/04/22	140.16KB	Share
MSB	Becoming a substantial holder		29/03/22	431.35KB	Share
MSB	Initial Director's Interest Notice		28/03/22	192.95KB	Share
MSB	Director Appointment		24/03/22	175.28KB	Share
MSB	S&P DJI Announces March 2022 Quarterly Rebalance	PRICE SENSITIVE	04/03/22	175.5KB	Share
MSB	Final Director's Interest Notice		25/02/22	189.61KB	Share
MSB	MSB Q2 Financial Results and Operational Highlights	PRICE SENSITIVE	25/02/22	654.15KB	Share
MSB	Second Quarter Results Presentation	PRICE SENSITIVE	25/02/22	2.82MB	Share
MSB	Half Yearly Report and Accounts	PRICE SENSITIVE	25/02/22	948.77KB	Share
MSB	Mesoblast Q2 Financial Results Webcast		24/02/22	114.99KB	Share
MSB	Ulcerative Colitis & Crohns Results Presented at ECCO	PRICE SENSITIVE	21/02/22	192.81KB	Share
MSB	Mesoblast Appoints Dr Eric Rose as Chief Medical Officer		02/02/22	193.54KB	Share
MSB	Appendix 4C Quarterly Activity Report	PRICE SENSITIVE	31/01/22	340.86KB	Share
MSB	MSB Presents at Edison Group Global Healthcare Conference		25/01/22	146.79KB	Share
MSB	Cleansing Notice and Appendix 2A		18/01/22	489.88KB	Share
MSB	Proposed issue of securities - MSB		18/01/22	26.45KB	Share
MSB	Appendix 3G, Appendix 3H and Appendix 3Y		17/01/22	543.81KB	Share
MSB	36-Month Results of Phase 3 Trial in Chronic Low Back Pain		12/01/22	158.05KB	Share
MSB	Biotech Showcase 2022 Presentation		12/01/22	3.36MB	Share
MSB	Prospectus for Warrants Related to Oaktree Debt Refinance		06/01/22	585.47KB	Share
MSB	Update on FDA Meeting for Remestemcel-L in Paediatric GvHD		31/12/21	178.48KB	Share
MSB	FDAs OTAT Agrees to Primary Endpoint for Back Pain	PRICE SENSITIVE	16/12/21	171.73KB	Share
MSB	Update on Novartis Agreement	PRICE SENSITIVE	14/12/21	129.26KB	Share
MSB	Pause in Trading	PRICE SENSITIVE	14/12/21	116.22KB	Share
MSB	Rexlemestrocel Greatest Benefit in Diabetics and Ischemics		06/12/21	226.31KB	Share
MSB	Global CardioVascular Clinical Trialists Forum Presentation		06/12/21	1.65MB	Share
MSB	Results of Meeting		29/11/21	153.78KB	Share
MSB	CEO Presentation to 2021 Annual General Meeting		29/11/21	3.74MB	Share

MSB Prospectus for Warrants Related to Oaktree Facility
03/03/23		509.39KB	Share
MSB DREAM HF Trial Published in JACC
28/02/23	PRICE SENSITIVE	226.95KB	Share
MSB MSB Q2 Financial Results and Operational Highlights
28/02/23	PRICE SENSITIVE	408.95KB	Share
MSB Second Quarter Results Presentation
28/02/23		1.57MB	Share
MSB Half Yearly Report and Accounts
28/02/23	PRICE SENSITIVE	1.67MB	Share
MSB Mesoblast Second Quarter Financial Results Webcast
27/02/23		115.2KB	Share
MSB Remestemcel Clinical and Potency Studies Presented at Tandem
17/02/23		175.63KB	Share
MSB FDA Grants RMAT Designation for Rexlemestrocel-L in CLBP
09/02/23		187.83KB	Share
MSB Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD
01/02/23	PRICE SENSITIVE	195.59KB	Share
MSB Quarterly Activities/Appendix 4C Cash Flow Report
31/01/23	PRICE SENSITIVE	419.11KB	Share
MSB Appendix 3G, Appendix 3H and Appendix 3Ys
16/01/23		575.59KB	Share
MSB Biotech Showcase 2023 Presentation in San Francisco
10/01/23		1.67MB	Share
MSB Extension of Undrawn US$30 million Facility
23/12/22	PRICE SENSITIVE	161.36KB	Share
MSB Proposed issue of securities - MSB
23/12/22		25.9KB	Share
MSB Appendix 3G, Appendix 3H and Appendix 3Y
02/12/22		582.16KB	Share
MSB Amended Constitution
24/11/22		626.04KB	Share
MSB Results of Meeting
23/11/22		187.96KB	Share
MSB Chairman's Address to Shareholders
23/11/22		192.3KB	Share
MSB Long-Term Survival for Acute GvHD Treatment with Remestemcel
23/11/22	PRICE SENSITIVE	189.85KB	Share
MSB MSB Q1 Financial Results and Operational Highlights
23/11/22	PRICE SENSITIVE	439.61KB	Share
MSB CEO First Quarter Results and 2022 AGM Presentation
23/11/22		2.06MB	Share
MSB First Quarter Financial Results on Form 6-K
23/11/22	PRICE SENSITIVE	500.21KB	Share
MSB Mesoblast First Quarter Financial Results Webcast
21/11/22		113.78KB	Share
MSB Removal of Amendment to Constitution About Virtual Meetings
15/11/22		123.99KB	Share
MSB Quarterly Activities/Appendix 4C Cash Flow Report
31/10/22	PRICE SENSITIVE	419.32KB	Share
MSB Notice of Annual General Meeting and Proxy Form
24/10/22		443.56KB	Share
MSB Annual Report to Shareholders
24/10/22		6.59MB	Share
MSB Appendix 4G and Corporate Governance Statement
24/10/22		412.08KB	Share
MSB Notification of cessation of securities - MSB
14/10/22		21.69KB	Share
MSB Submits New Information to FDA IND File for SR-aGVHD
03/10/22	PRICE SENSITIVE	168.87KB	Share
MSB Change of Director's Interest Notice
20/09/22		229.59KB	Share
MSB Change of Director's Interest Notice
12/09/22		226.98KB	Share
MSB MSB Annual Financial Results and Operational Highlights
31/08/22	PRICE SENSITIVE	386.1KB	Share
MSB Annual Financial Results Presentation
31/08/22		1.83MB	Share
MSB Preliminary Final Report
31/08/22	PRICE SENSITIVE	3.16MB	Share
MSB Mesoblast 2022 Full Year Financial Results Webcast
30/08/22		116.05KB	Share
MSB Director Appointment
18/08/22		133.74KB	Share
MSB Initial Director's Interest Notice
18/08/22		305.67KB	Share
MSB Final Director's Interest Notice
18/08/22		220.39KB	Share
MSB Ceasing to be a substantial holder - Tiga Trading Pty Ltd
16/08/22		306.57KB	Share
MSB Ceasing to be a substantial holder from TEK
16/08/22		324.86KB	Share
MSB Ceasing to be a substantial holder from TOP
16/08/22		320.64KB	Share
MSB Change in substantial holding
16/08/22		491.21KB	Share
MSB Cleansing Notice
12/08/22		176.58KB	Share
MSB Appendix 2A
12/08/22		357.17KB	Share
MSB Appendix 3B
09/08/22		652.66KB	Share
MSB US$45 Million Private Placement to Major Shareholders
09/08/22	PRICE SENSITIVE	157.61KB	Share
MSB Reinstatement to Quotation
09/08/22	PRICE SENSITIVE	85.62KB	Share
MSB Voluntary Suspension
08/08/22	PRICE SENSITIVE	221.75KB	Share
MSB Trading Halt
04/08/22	PRICE SENSITIVE	206.88KB	Share
MSB Pause in Trading
04/08/22	PRICE SENSITIVE	116.13KB	Share
MSB Quarterly Activities/Appendix 4C Cash Flow Report
29/07/22	PRICE SENSITIVE	444.42KB	Share
MSB Rexlemestrocel-L Improves LVEF, Preceding Reduction in MACE
19/07/22	PRICE SENSITIVE	185.89KB	Share
MSB Appendix 3H and Appendix 3Y
14/07/22		350.16KB	Share
MSB Rexlemestrocel-L to be Highlighted on Heart Failure Panel
12/07/22		167.56KB	Share
MSB Mesoblast CLBP Event with Key Opinion Leaders
21/06/22		168.79KB	Share
MSB Chronic Low Back Pain KOL Event Presentation
21/06/22		6.92MB	Share
MSB Litigation Update
14/06/22		172.01KB	Share
MSB Mesoblast to Host KOL Event on Chronic Low Back Pain
09/06/22		168.93KB	Share
MSB Third Quarter Results Presentation
01/06/22	PRICE SENSITIVE	2.69MB	Share
MSB MSB Q3 Financial Results and Operational Highlights
01/06/22	PRICE SENSITIVE	402.97KB	Share
MSB Third Quarter Financial Results on Form 6-K
01/06/22	PRICE SENSITIVE	577.99KB	Share
MSB Mesoblast Q3 Financial Results Webcast
31/05/22		115.5KB	Share
MSB Remestemcel-L Survival Outcomes in COVID-19 ARDS Patients
31/05/22		179.19KB	Share
MSB Ceasing to be a substantial holder
30/05/22		1.08MB	Share
MSB Becoming a substantial holder
20/05/22		1.39MB	Share
MSB Litigation Update
19/05/22		172.93KB	Share
MSB Ceasing to be a substantial holder
03/05/22		1.05MB	Share
MSB Ceasing to be a substantial holder
02/05/22		162.97KB	Share
MSB Quarterly Activities/Appendix 4C Cash Flow Report
29/04/22	PRICE SENSITIVE	443.8KB	Share
MSB Becoming a substantial holder
19/04/22		1.29MB	Share
MSB Appendix 3G and Appendix 3H
14/04/22		428.72KB	Share
MSB Company Secretary Appointment
06/04/22		140.16KB	Share
MSB Becoming a substantial holder
29/03/22		431.35KB	Share
MSB Initial Director's Interest Notice
28/03/22		192.95KB	Share
MSB Director Appointment
24/03/22		175.28KB	Share
MSB S&P DJI Announces March 2022 Quarterly Rebalance
04/03/22	PRICE SENSITIVE	175.5KB	Share
MSB Final Director's Interest Notice
25/02/22		189.61KB	Share
MSB MSB Q2 Financial Results and Operational Highlights
25/02/22	PRICE SENSITIVE	654.15KB	Share
MSB Second Quarter Results Presentation
25/02/22	PRICE SENSITIVE	2.82MB	Share
MSB Half Yearly Report and Accounts
25/02/22	PRICE SENSITIVE	948.77KB	Share
MSB Mesoblast Q2 Financial Results Webcast
24/02/22		114.99KB	Share
MSB Ulcerative Colitis & Crohns Results Presented at ECCO
21/02/22	PRICE SENSITIVE	192.81KB	Share
MSB Mesoblast Appoints Dr Eric Rose as Chief Medical Officer
02/02/22		193.54KB	Share
MSB Appendix 4C Quarterly Activity Report
31/01/22	PRICE SENSITIVE	340.86KB	Share
MSB MSB Presents at Edison Group Global Healthcare Conference
25/01/22		146.79KB	Share
MSB Cleansing Notice and Appendix 2A
18/01/22		489.88KB	Share
MSB Proposed issue of securities - MSB
18/01/22		26.45KB	Share
MSB Appendix 3G, Appendix 3H and Appendix 3Y
17/01/22		543.81KB	Share
MSB 36-Month Results of Phase 3 Trial in Chronic Low Back Pain
12/01/22		158.05KB	Share
MSB Biotech Showcase 2022 Presentation
12/01/22		3.36MB	Share
MSB Prospectus for Warrants Related to Oaktree Debt Refinance
06/01/22		585.47KB	Share
MSB Update on FDA Meeting for Remestemcel-L in Paediatric GvHD
31/12/21		178.48KB	Share
MSB FDAs OTAT Agrees to Primary Endpoint for Back Pain
16/12/21	PRICE SENSITIVE	171.73KB	Share
MSB Update on Novartis Agreement
14/12/21	PRICE SENSITIVE	129.26KB	Share
MSB Pause in Trading
14/12/21	PRICE SENSITIVE	116.22KB	Share
MSB Rexlemestrocel Greatest Benefit in Diabetics and Ischemics
06/12/21		226.31KB	Share
MSB Global CardioVascular Clinical Trialists Forum Presentation
06/12/21		1.65MB	Share
MSB Results of Meeting
29/11/21		153.78KB	Share
MSB CEO Presentation to 2021 Annual General Meeting
29/11/21		3.74MB	Share

REFRESH

First 2 3 4 5 6

(20min delay)
Last $1.09		Change 0.015(1.40%)		Mkt cap ! $1.238B

Open	High	Low	Value	Volume
$1.11	$1.12	$1.08	$11.51M	10.52M

Buyers (Bids)

No.	Vol.	Price($)
2	17804	$1.09

Sellers (Offers)

Price($)	Vol.	No.
$1.09	230637	5

View Market Depth

No.	Vol.	Price($)
1	2500	1.085
8	103868	1.080
4	20400	1.075
11	85089	1.070
4	50577	1.065

Price($)	Vol.	No.
1.090	5437	2
1.095	19582	2
1.100	34717	4
1.105	10000	1
1.110	53313	3

Last trade - 16.10pm 03/05/2024 (20 minute delay)


Last $1.09		Change 0.015 ( 1.85 %)
Open	High	Low	Volume
$1.10	$1.12	$1.08	1937390
Last updated 15.59pm 03/05/2024 ?

MSB (ASX) Chart

MESOBLAST LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories